New data from ADA 2026 reveal that assumptions around age, weight, and gestational history are leaving too many T1D patients ...
In today's Pharmaceutical Executive Daily, the FDA approves Gilead's Trodelvy for the first-line treatment of metastatic ...
Approval establishes sacituzumab govitecan as a first-line option across PD-L1 strata, including monotherapy when checkpoint inhibitors are unsuitable and combination therapy for PD-L1 CPS ≥10 tumors.
In today's Pharmaceutical Executive Daily, AbbVie announces a $10.9 billion agreement to acquire Apogee Therapeutics, adding ...
Capvaxive uniquely adds eight adult-predominant invasive serotypes absent from other approved pneumococcal vaccines, ...
FDA approved Utebzi, an oral carbapenem antibiotic developed by GSK in partnership with Spero Therapeutics, for the treatment ...
They want to make sure we've got more control over that supply chain, so DARPA and the federal government are really ...
Clinical Affairs plays a central role in ensuring that CGM promotional claims are accurate, evidence-based, and compliant. By ...
Silvia Taylor of Novavax details how the company leverages its expertise in vaccine development to build partnerships across ...
CHMP recommended EU marketing authorization for pirtobrutinib in adult CLL across all therapy lines, regardless of prior BTK inhibitor treatment history. BRUIN CLL-313 and CLL-314 supported meaningful ...
As Connecticut moves to rein in private equity's playbook in hospital deals, pharma and life sciences leaders face a parallel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results